A longitudinal study of plasma acylcarnitines throughout pregnancy and associations with risk of gestational diabetes mellitus
A longitudinal study of plasma acylcarnitines throughout pregnancy and associations with risk of gestational diabetes mellitus
复制标题
DOI：
10.1016/j.clnu.2021.07.008
复制
发表时间：
2021-08-01
影响因子：
6.3
通讯作者：
Zhang, Cuilin
中科院分区：
文献类型：
--
作者：
Lin, Yuan;Wu, Jing;Zhang, Cuilin
背景与目的：目前缺乏关于酰基肉毒碱类药物与妊娠期糖尿病（GDM）相关性的前瞻性和纵向数据。本研究旨在前瞻性研究28酰基肉毒碱与随后GDM风险的关系。研究方法：在NICHD胎儿生长发育-单胎队列中，在107例GDM病例和214例对照中，在妊娠周（GW）10-14、15-26、23-31和33-39测量酰基肉毒碱和心脏代谢生物标志物的血浆水平。结果如下：在GW 10-14时，根据标准差（SD），C14：1-OH水平增加与调整GDM主要风险因素后GDM风险增加55%相关[OR（95%CI）：1.55（1.05-2.29）]。在GW 15-26，C4、C8：1和C16：1-OH与GDM风险增加相关[每SD增加的OR（95% CI）分别为：1.42（1.01-2.0 0）、1.41（1.02-1.96）和1.77（1.10-2.84）]。而C10和C18增加与GDM风险降低相关[每SD增加的OR（95%CI）分别为：0.74（0.55-1.0 0）和0.69（0.49-0.97）]。此外，我们还观察到非GDM妇女中酰基肉毒碱与葡萄糖稳态和心脏代谢功能相关的多种临床标志物之间的相关性。结论：我们的研究结果表明，几种血浆酰基肉毒碱物种与GDM的风险链长度的差异。未来的研究是必要的，以探讨不同的作用，个别酰基肉毒碱在葡萄糖稳态妊娠。由Elsevier Ltd.发布。这是CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Background & aims: Prospective and longitudinal data on the association between acylcarnitines and gestational diabetes (GDM) are lacking. This study aims to prospectively investigate 28 acylcarnitines in relation to subsequent GDM risk. Methods: Within the NICHD Fetal Growth Studies-Singleton Cohort, plasma levels of acylcarnitines and cardiometabolic biomarkers were measured at gestational week (GW) 10-14, 15-26, 23-31, and 33-39 among 107 GDM cases and 214 controls. Results: At GW 10-14, per standard deviation (SD) increased level of C14:1-OH was associated with a 55% increased risk of GDM after adjusting for major risk factors for GDM [OR (95% CI): 1.55 (1.05-2.29)]. At GW 15-26, C4, C8:1 and C16:1-OH were associated with an increased risk of GDM [OR (95% CI) for per SD increase: 1.42 (1.01-2.0 0), 1.41 (1.02-1.96), and 1.77 (1.10-2.84), respectively]. Whereas increased C10 and C18 were related to lower risk of GDM [OR (95% CI) for per SD increase: 0.74 (0.55-1.0 0), and 0.69 (0.49-0.97), respectively]. Moreover, we observed correlations of individual acylcarnitine with multiple clinical markers implicated in glucose homeostasis and cardiometabolic function among nonGDM women. Conclusions: Our results demonstrate that several plasma acylcarnitine species are differentially associated with GDM risk by chain length. Future studies are warranted to investigate the distinct roles of individual acylcarnitine in glucose homeostasis in pregnancy. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).